Previously, Neurogen entered into an agreement to sell the facilities for $6 million, subject to conditions customary for commercial real estate transactions. Neurogen continues to pursue the monetization
The echocardiography guided cardiac resynchronization therapy (EchoCRT) trial is said to be the largest prospective, randomized, double-blind, international, multicenter clinical trial of its kind. It is designed to
According to the company, the Sprinter Legend (semicompliant) balloon catheter provides the latest innovations in balloon technology and is well equipped to address difficult lesions in coronary angioplasty
According to the company, significant positive results were achieved, clearly demonstrating the efficacy and safety of this simple, low-cost method to reduce pain within the first few days
Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with
The trial was conducted in 16 healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response
The patent stems from a provisional patent application filed in the US Patent & Trademark Office (USPTO) in 2000 by the University of Melbourne. In 2007, MorphoSys signed
Under the terms of the merger agreement, King’s tender offer for all of the outstanding shares of class A common stock of Alpharma will be extended and will
Under the terms of the agreement, Johnson & Johnson (J&J) will commence a tender offer to purchase all outstanding shares of Omrix at $25 per share, which is
The alliance spans all activities from target discovery through to completion of proof of concept clinical trials of novel therapeutic antibodies. Both companies will contribute their core technologies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.